They advocated that adjuvant treatment might also be considered in patients with HER2+ tumors <6 mm when factors such as HR negativity, increased Ki-67 and/or poor nuclear grade suggest aggressive tumor biology. This evidence concerns the gene ERBB2 and neoplasm.